191 related articles for article (PubMed ID: 22473827)
1. Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN.
Antonioli E; Guglielmelli P; Pieri L; Finazzi M; Rumi E; Martinelli V; Vianelli N; Luigia Randi M; Bertozzi I; De Stefano V; Za T; Rossi E; Ruggeri M; Elli E; Cacciola R; Cacciola E; Pogliani E; Rodeghiero F; Baccarani M; Passamonti F; Finazzi G; Rambaldi A; Bosi A; Cazzola M; Barbui T; Vannucchi AM;
Am J Hematol; 2012 May; 87(5):552-4. PubMed ID: 22473827
[TBL] [Abstract][Full Text] [Related]
2. Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug.
Latagliata R; Spadea A; Cedrone M; Di Giandomenico J; De Muro M; Villivà N; Breccia M; Anaclerico B; Porrini R; Spirito F; Rago A; Avvisati G; Alimena G; Montanaro M; Andriani A;
Cancer; 2012 Jan; 118(2):404-9. PubMed ID: 21692060
[TBL] [Abstract][Full Text] [Related]
3. [Hydroxyurea-induced leg ulcers in patients with chronic myeloproliferative disorders].
Olesen LH; Pedersen BB
Ugeskr Laeger; 2001 Dec; 163(49):6908-11. PubMed ID: 11766504
[TBL] [Abstract][Full Text] [Related]
4. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan.
Nielsen I; Hasselbalch HC
Am J Hematol; 2003 Sep; 74(1):26-31. PubMed ID: 12949887
[TBL] [Abstract][Full Text] [Related]
5. Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review.
Malato A; Rossi E; Palumbo GA; Guglielmelli P; Pugliese N
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32486130
[TBL] [Abstract][Full Text] [Related]
6. Toxicity and side effects of hydroxyurea used for primary thrombocythemia.
Randi ML; Ruzzon E; Tezza F; Luzzatto G; Fabris F
Platelets; 2005; 16(3-4):181-4. PubMed ID: 16011962
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders.
Ravandi-Kashani F; Cortes J; Cohen P; Talpaz M; O'Brien S; Markowitz A; Kantarjian H
Leuk Lymphoma; 1999 Sep; 35(1-2):109-18. PubMed ID: 10512168
[TBL] [Abstract][Full Text] [Related]
8. Busulfan is effective second-line therapy for older patients with Philadelphia-negative myeloproliferative neoplasms intolerant of or unresponsive to hydroxyurea.
Douglas G; Harrison C; Forsyth C; Bennett M; Stevenson W; Hounsell J; Ratnasingam S; Ritchie D; Ross DM; Grigg A
Leuk Lymphoma; 2017 Jan; 58(1):89-95. PubMed ID: 27454522
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea-associated squamous dysplasia.
Sanchez-Palacios C; Guitart J
J Am Acad Dermatol; 2004 Aug; 51(2):293-300. PubMed ID: 15280852
[TBL] [Abstract][Full Text] [Related]
10. Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders.
Randi ML; Ruzzon E; Luzzatto G; Tezza F; Girolami A; Fabris F
Haematologica; 2005 Feb; 90(2):261-2. PubMed ID: 15710584
[TBL] [Abstract][Full Text] [Related]
11. Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms.
Hansen IO; Sørensen AL; Hasselbalch HC
Eur J Haematol; 2017 Jan; 98(1):75-84. PubMed ID: 27471124
[TBL] [Abstract][Full Text] [Related]
12. Dermatomyositis-like eruption after long-term hydroxyurea therapy for polycythemia vera.
Oskay T; Kutluay L; Ozyilkan O
Eur J Dermatol; 2002; 12(6):586-8. PubMed ID: 12459535
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of chronic myeloid leukemia using alpha-interferon and hydroxyurea. Study of 30 cases].
Nese M; de Bellis R; Urtiarte R; Di Landro J
Sangre (Barc); 1994 Jun; 39(3):183-6. PubMed ID: 7940047
[TBL] [Abstract][Full Text] [Related]
14. Concurrent basal cell and squamous cell carcinomas associated with hydroxyurea therapy.
Radić J; Batinac T; Hadžisejdić I; Načinović-Duletić A; Valković T; Jonjić N
Acta Dermatovenerol Croat; 2011; 19(3):183-6. PubMed ID: 21933645
[TBL] [Abstract][Full Text] [Related]
15. Multiple squamous cell carcinomas of the skin during long-term treatment with hydroxyurea.
De Simone C; Guerriero C; Guidi B; Rotoli M; Venier A; Tartaglione R
Eur J Dermatol; 1998 Mar; 8(2):114-5. PubMed ID: 9649662
[TBL] [Abstract][Full Text] [Related]
16. Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease.
Grigg A
Intern Med J; 2007 Mar; 37(3):190-2. PubMed ID: 17316339
[TBL] [Abstract][Full Text] [Related]
17. Scleroderma-like syndrome due to hydroxyurea.
García-Martínez FJ; García-Gavín J; Alvarez-Pérez A; Alonso-González J; Ginarte M; Toribio J
Clin Exp Dermatol; 2012 Oct; 37(7):755-8. PubMed ID: 22439735
[TBL] [Abstract][Full Text] [Related]
18. [Dermatologic complications of long-term hydroxyurea therapy].
Mokni S; Fetoui Ghariani N; Aounallah A; Fathallah N; Boussofara L; Saidi W; Ben Salem C; Sriha B; Belajouza C; Denguezli M; Ghariani N; Nouira R
Therapie; 2017 Jun; 72(3):391-394. PubMed ID: 27912970
[No Abstract] [Full Text] [Related]
19. [Cutaneous side effects of a long-term treatment by hydroxyurea].
Steels E; Heenen M; Germaux MA; Moens JP
Rev Med Brux; 2006; 27(1):39-41. PubMed ID: 16608010
[TBL] [Abstract][Full Text] [Related]
20. Successful long-term treatment of Philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide.
Ahn IE; Natelson E; Rice L
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S300-4. PubMed ID: 24290215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
